复方青黛丸联合阿维A及卡泊三醇治疗中、重度寻常性银屑病34例临床观察

A Clinical Study of Compound Qingdai Pill Combined with Acitretin and Calcipotriol in the Treatment of Patients with Moderate to Severe Psoriasis Vulgaris

目的评价复方青黛丸联合阿维A及卡泊三醇治疗中、重度寻常性银屑病的临床疗效和安全性。方法将入选的67例中、重度寻常性银屑病患者随机分为2组,全部患者予口服阿维A胶囊0.4mg/(kg·d),卡泊三醇乳膏外搽(2次/d)。治疗组(34例)同时还予口服复方青黛丸6g(3次/d),两组患者疗程均8周。结果治疗8周后,治疗组PASI评分(4.11±3.11)低于对照组PASI评分(5.94±2.97),治疗组有效率(93.93%)高于对照组有效率(75.75%),差异均有统计学意义(P均<O.05)。另外,两组患者治疗过程中未见发生明显不良反应。结论复方青黛丸联合阿维A及卡泊三醇治疗中、重度寻常性银屑病的疗效好,安全性可靠。

Objective To evaluate the efficacy and safety of Compound qingdai pill combined with Acitretin and Calcipotriol in patients with moderate to severe psoriasis vulgaris. Methods Sixty-seven cases with moderate to severe psoriasis vulgaris were divided into two groups and treated for 8 weeks. The treatment group was treated with Compound qingdai pill 6g （rid） combined with Acitretin 0.4mg/ （ kg ~ d） and Calcipotriol ointment twice daily, the control group was treated with Aeitretin 0.4mg,/ （ kg ~ d） and Caleipotriol ointment twice daily. Then evaluate the efficacy and the adverse reaction of treatment by psoriasis area and severity Index （PASI） scores. Results The PASI scores in the treatment group（4. 11±3. 11） were significantly lower than that of control group（5.94±2. 97 ） （ P 〈 0. 05 ）. The efficacy rates in the treatment group （ 93. 93% ） were significantly higher than that of control group（ 75.75% ） （P 〈0.05 ）. There was no obvious adverse reaction occurred in both two groups. Conclusion Compound qingdai pill combined with Acitretin and Calcipotriol showed good efficacy and safety for moderate to severe psoriasis vulgaris patients.